Adalimumab in active ulcerative colitis: A "real-life" observational study

Published on Mar 1, 2012in Digestive and Liver Disease3.037
· DOI :10.1016/j.dld.2013.03.018
Alessandro Armuzzi41
Estimated H-index: 41
Livia Biancone38
Estimated H-index: 38
+ 28 AuthorsClaudio Papi31
Estimated H-index: 31
a b s t r a c t Background and aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods: All patients with active disease treated with adalimumab were retrospectively reviewed. Co- primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results: Eighty-eight patients were included. Most patients had received previous infliximab treatment. Clinical remission rates were 17%, 28.4%, 36.4% and 43.2% at 4, 12, 24 and 54 weeks respectively. Twenty- two patients required colectomy. Clinical remission and low C-reactive protein at week 12 predicted clinical remission at week 54 (OR 4.17, 95% CI 2.36-19.44; OR 2.63, 95% CI 2.32-14.94, respectively). Previous immunosuppressant use was associated with a lower probability of clinical remission at week 54 (OR 0.67, 95% CI 0.08-0.66) and with a higher rate of colectomy (HR 9.7, 95% CI 1.46-9.07). Conclusion: In this large "real-life" experience adalimumab appears effective in patients with otherwise medically refractory ulcerative colitis. Patients achieving early remission can expect a better long-term outcome.
  • References (25)
  • Citations (44)
📖 Papers frequently viewed together
631 Citations
13 Authors (Walter Reinisch, ..., Roopal Thakkar)
487 Citations
2,481 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Alessandro Armuzzi (UCSC: Catholic University of the Sacred Heart)H-Index: 41
#2Daniela Pugliese (UCSC: Catholic University of the Sacred Heart)H-Index: 13
Last. Luisa Guidi (UCSC: Catholic University of the Sacred Heart)H-Index: 29
view all 13 authors...
BACKGROUND: Up to 20% of patients with ulcerative colitis (UC) become steroid-dependent during their course. Thiopurines are recommended in steroid-dependent UC, but their efficacy is debated. Data exploring the use of infliximab in these patients are scarce. Aims of this study were to evaluate the effectiveness of infliximab in steroid-dependent UC and identify predictors of steroid-free remission, mucosal healing (MH), and colectomy. METHODS: Steroid-dependent UC patients were enrolled and int...
47 CitationsSource
#1Edel McDermottH-Index: 8
#2Seamus J. MurphyH-Index: 3
Last. Glen A. DohertyH-Index: 23
view all 6 authors...
Abstract Introduction Adalimumab is a recombinant human IgG1 monoclonal antibody to TNF-alpha. There are limited data with regard to its efficacy in ulcerative colitis. We report experience of adalimumab in ulcerative colitis in a single centre with a focus on the ability of this agent to maintain response and avoid colectomy in the medium to long-term. Methods Twenty-three ulcerative colitis patients (mean age 32 years; 7 female) who received adalimumab were identified from a prospectively main...
33 CitationsSource
#1Axel DignassH-Index: 33
#2Rami EliakimH-Index: 56
Last. G. Van AsscheH-Index: 82
view all 13 authors...
### 1.1 Introduction Ulcerative colitis is a lifelong disease arising from an interaction between genetic and environmental factors, observed predominantly in the developed countries of the world. The precise aetiology is unknown and therefore medical therapy to cure the disease is not yet available. Within Europe there is a North–South gradient, but the incidence appears to have increased in Southern and Eastern countries in recent years.1,2 Patients may live with a considerable symptom burden ...
489 CitationsSource
#1WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 142
#2G. Van Assche (Katholieke Universiteit Leuven)H-Index: 82
Last. Roopal ThakkarH-Index: 20
view all 10 authors...
Background & Aims Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor (TNF)-α. Its efficacy as maintenance therapy for patients with ulcerative colitis has not been studied in a controlled, double-blind trial. Methods Ulcerative colitis long-term remission and maintenance with adalimumab 2 (ULTRA 2) was a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of adalimumab in induction and maintenance of clinical remission in 494 patients with mo...
631 CitationsSource
#1Jean-Frederic Colombel (university of lille)H-Index: 129
#2Paul Rutgeerts (Katholieke Universiteit Leuven)H-Index: 138
Last. WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 142
view all 15 authors...
Background & Aims In the Active Ulcerative Colitis Trial (ACT)-1 and ACT-2, patients with ulcerative colitis treated with infliximab were more likely than those given placebo to have a clinical response, undergo remission, and have mucosal healing. We investigated the association between early improvement (based on endoscopy) and subsequent clinical outcome. Methods Patients underwent endoscopic evaluations at weeks 0, 8, 30, and 54 (ACT-1 only), and were categorized into 4 subgroups by week 8 (...
487 CitationsSource
#1Walter Reinisch (Medical University of Vienna)H-Index: 74
#2WilliamJSandborn (Mayo Clinic)H-Index: 142
Last. Roopal ThakkarH-Index: 20
view all 13 authors...
Objective The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a recombinant human monoclonal antibody against tumour necrosis factor a (TNF), for the induction of clinical remission in anti-TNF nao¨ve patients with moderately to severely active ulcerative colitis. Methods This 8-week, multicentre, randomised, doubleblind, placebo-controlled study (NCT00385736), conducted at 94 centres in North America and Europe, enrolled ambulatory adult patients with Mayo score of ...
487 CitationsSource
#1C. TaxoneraH-Index: 7
#2Jesús EstellésH-Index: 5
Last. J. MendozaH-Index: 13
view all 16 authors...
Aliment Pharmacol Ther 2011; 33: 340–348 Summary Background The long-term efficacy of adalimumab in patients with ulcerative colitis is not well known. Aim To evaluate the short- and long-term outcomes of adalimumab in ulcerative colitis patients previously treated with infliximab. Methods Patients with active ulcerative colitis were treated with adalimumab after failure of other therapies including infliximab. Short-term clinical response and remission were assessed at weeks 4 and 12. The propo...
74 CitationsSource
#1Ambrogio Orlando (University of Palermo)H-Index: 28
#2Alessandro Armuzzi (CUA: The Catholic University of America)H-Index: 41
Last. Mario Cottone (University of Palermo)H-Index: 38
view all 15 authors...
Biological therapies are an important step in the management of Inflammatory Bowel Diseases. In consideration of high cost and safety issues there is the need to have clear recommendations for their use. Despite the American Gastroenterological Association and the European Crohn’s and Colitis Organisation have published exhaustive Inflammatory Bowel Disease guidelines, national guidelines may be necessary as cultural values, economical and legal issues may differ between countries. For these rea...
109 CitationsSource
#1Carlos TaxoneraH-Index: 28
#2Jesús EstellésH-Index: 5
Last. JuanLuisMendozaH-Index: 30
view all 16 authors...
54 CitationsSource
#1Remo Panaccione (U of C: University of Calgary)H-Index: 62
Last. Paul F. PollackH-Index: 24
view all 9 authors...
In the randomized, double-blind, placebo-controlled CHARM trial, adalimumab was more effective than placebo in maintaining clinical remission for patients with moderate-to-severe Crohn's disease (CD) through 56 weeks. To substantiate the long-term safety and clinical benefits of adalimumab through 2 years of therapy in CHARM and its open-label extension (ADHERE). Patients entering ADHERE on blinded therapy received adalimumab 40 mg every other week (eow). Patients who had already moved to open-l...
87 CitationsSource
Cited By44
#1Leif Angelison (Lund University)H-Index: 2
#2Sven Almer (Karolinska University Hospital)H-Index: 11
Last. Erik Hertervig (Lund University)H-Index: 21
view all 8 authors...
AbstractObjective: Randomized controlled trials have shown the effectiveness of Adalimumab in ulcerative colitis. However, real-life data is scarce. We aimed to assess the effectiveness and predict...
#1Samaneh Mohagheghi Darehranj (Tehran University of Medical Sciences)
#2Sudabeh Alatab (Tehran University of Medical Sciences)H-Index: 10
view all 13 authors...
BACKGROUND: The anti-TNF drugs are shown to be highly effective in treatment of patients with moderate-to-severe inflammatory bowel disease (IBD). Here, we aimed to assess the efficacy and safety of anti-TNF therapy at the national level. METHODS: IBD patients aged 15> years who received Infliximab and/ or CinnoRA® between 2013 to July 2018 were identified. The data extracted from medical dossier and telephonic interview. The efficacy of therapy was defined as time to drug discontinuation or nee...
AbstractBackground: Biologics used to treat ulcerative colitis (UC) may lose their effect over time, requiring patients to undergo dose escalation or treatment switching, and systematic literature ...
#1Salvatore Bellinvia (University Hospital Southampton NHS Foundation Trust)H-Index: 1
#2J. R. Fraser Cummings (University Hospital Southampton NHS Foundation Trust)H-Index: 4
Last. Christopher J. Edwards (University Hospital Southampton NHS Foundation Trust)H-Index: 40
view all 4 authors...
Adalimumab, the first fully humanised monoclonal antibody against tumour necrosis factor alpha (TNF-α), has played a leading role in the revolution brought about by the introduction of biologics, and has received the widest range of indications among TNF-α inhibitors. Post-registration, observational and registry studies of real-life use have largely supported the outcomes seen in registrational clinical trials. With the recent loss of exclusivity for the originator medicinal product in Europe, ...
Abstract Background In patients with chronic refractory ulcerative colitis (UC) the precise timing for indication to colectomy is unclear. Aims We performed a systematic review of the literature on the risk factors for colectomy in patients with chronic refractory UC in the biologic era. Methods PubMed Central/Medline and Embase were systemically searched for records published between January 2000 and December 2017. Current evidence was summarized and filtered by expert opinion. Results 70 studi...
#1Anna Viola (UNIME: University of Messina)H-Index: 3
#2Daniela Pugliese (CUA: The Catholic University of America)H-Index: 13
Last. Walter Fries (UNIME: University of Messina)H-Index: 28
view all 15 authors...
Abstract Background Anti-TNF therapies infliximab (IFX), adalimumab (ADA), and golimumab (GOL) are approved for treating moderate to severe ulcerative colitis (UC). In UC, only the switch from IFX to ADA has been investigated, reaching no more than 10–43% remission rates at 12 months. Aim Of the present study was to investigate disease outcome after a switch from subcutaneous (SC) agents to the intravenous (IV) agent (IFX). Methods In this retrospective multicentre study, we analysed the charts ...
#2Wolfgang SchmidtH-Index: 1
Last. Martin Emmert (FAU: University of Erlangen-Nuremberg)H-Index: 15
view all 5 authors...
Aims We determined adalimumab utilisation and associated drug costs in patients with ulcerative colitis (UC), focusing on patients requiring dose escalation.
1 CitationsSource
#1Alessandro Sartini (UNIBO: University of Bologna)H-Index: 7
#2Eleonora Scaioli (UNIBO: University of Bologna)H-Index: 15
Last. Andrea Belluzzi (UNIBO: University of Bologna)H-Index: 30
view all 7 authors...
Background “Real-life” data of retention rate and persistence of adalimumab in inflammatory bowel disease are still limited.
2 CitationsSource
Abstract Background Adalimumab is the second tumour necrosis factor antagonist (anti-TNF) adopted for the treatment of ulcerative colitis. Clinical data from naive patients are scarce. Aim Examine the response to adalimumab in TNF-antagonist-naive patients. Methods This multicentre, observational, prospective study was conducted using a cohort of consecutive patients with ulcerative colitis. Clinical remission, mucosal healing and deep remission were examined employing the Mayo Score and Mayo En...
1 CitationsSource
#1A. Barré (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
#2Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 129
Last. Ryan C. Ungaro (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 11
view all 3 authors...
SummaryBackground Increased knowledge of pathways involved in the pathogenesis of IBD has led to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis (UC). Two new biological agents have been recently approved for IBD: vedolizumab and ustekinumab. They have different therapeutic targets (α4β7 integrin for vedolizumab and interleukin-12/23 pathways for ustekinumab) than the primary biological class, anti-tumour necrosis factor alpha (anti-TNF) agents. As the ar...
19 CitationsSource